Research Associate /Research Fellow in Organic PET Radiochemistry
The role is to perform radiopharmaceutics research and provide specialist expertise as a radiochemist within a multidisciplinary EPSRC-funded Programme: Next Generation Radiochemistry for Molecular Imaging with Radionuclides (MITHRAS), based at King’s College London, Imperial College and the University of Southampton. The team will include specialists in radionuclide production, nanodrug and cell therapy researchers, organic and inorganic radiochemists, and molecular imaging biologists, and will be embedded within a wider collaborative network comprising the Imaging Chemistry and Biology Department and the School of Biomedical Engineering and Imaging Sciences at King’s, and a network of major internal and external collaborations with other major London universities and hospitals. The aim of the programme is to develop new chemistry for fast, accessible synthesis of radiopharmaceuticals, and translate this into clinically translatable products for imaging and radionuclide therapy
This post holder will bring skills in PET organic radiochemistry (11C, 18F,13N and 34mCl) and will have the specific role of discovering, developing and implementing ‘organic’ radiochemistry with short lived radionuclides including 11C, 18F and 13N, focusing on new, faster and simpler radiochemistry to incorporate these radionuclides into useful synthons and using them to synthesise new tracers. The post holder will also develop new radiochemistry for C-Cl, Cl-O bond formation and incorporating 34mCl into new radiopharmaceuticals (e.g. chloro-aromatics and inorganic ions).
Radiopharmaceuticals produced will undergo preclinical evaluation in collaboration with our preclinical imaging team to implement and investigate short-lived multi-tracer PET imaging applications. The role will encompass varied responsibilities, including work on a wide range of collaborative projects.
The incumbent will work collaboratively with research groups both across the City of London Major Centre (University College London, the Francis Crick Institute and other King’s partners) and elsewhere, to drive the development and translation of radionuclide-based molecular imaging and therapy agents.